INTS
Intensity·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
INTS Profile
Intensity Therapeutics, Inc.
A clinical-stage biotechnology company whose treatment approach addresses both the regional and systemic nature of a patient’s cancer.
Biological Technology
11/30/2012
06/30/2023
NASDAQ Stock Exchange
5
12-31
Common stock
1 Enterprise Drive, Suite 430, Shelton, CT 06484-4779
--
Intensity Therapeutics, Inc., was incorporated in Delaware on November 30, 2012. The company is a clinical-stage biotechnology company that has pioneered a new immune-based approach to the treatment of solid tumor cancers. The company uses its DfuseRx technology platform to create patented drug formulations that, after direct injection, rapidly spread throughout the tumor and the therapeutic agent into cancer cells. The company's product candidate has the potential to induce an adaptive immune response that can attack not only injected tumors but also uninjected tumors. The company's main product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer.
